Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Neuroscience Right
  3. Tauvid (flortaucipir F18 injection) Right
  4. How much radiation does Tauvid™ (flortaucipir F 18) expose a patient to?
Search Tauvid (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Tauvid ™ (flortaucipir F18 injection)

300-3700 MBq/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How much radiation does Tauvid™ (flortaucipir F 18) expose a patient to?

The effective radiation dose from a 370-MBq (10 mCi) dose of Tauvid (flortaucipir F 18) is 8.7 mSv. The organs with the highest radiation-absorbed doses were the upper intestinal wall, small intestines, and liver.

US_cFAQ_FTP003_RADIATION_EXPOSURE
US_cFAQ_FTP003_RADIATION_EXPOSURE
en-US

Radiation Dosimetry

Following intravenous administration of flortaucipir F 18, the drug was distributed throughout the body with less than

  • 10% of the injected F 18 radioactivity present in the blood by 5 minutes following administration, and
  • 5% present in the blood by 10 minutes after administration.1

The estimated radiation-absorbed doses for an average adult weighing 70 kg from intravenous injection of flortaucipir F 18 are shown in Estimated Radiation Absorbed Dose After a Flortaucipir F 18 Injection. The organs with the highest radiation-absorbed doses were the

  • upper large intestinal wall
  • small intestines, and
  • liver.1,2
Estimated Radiation Absorbed Dose After a Flortaucipir F 18 Injection1,2

Organ/Tissue

Mean Absorbed Dose Per Unit
Administered Activity (µGy/MBq)

Adrenal glands

14

Brain

8

Breasts

7

Gallbladder wall

38

Lower large intestine wall

35

Small intestine wall

85

Stomach wall

13

Upper large intestine wall

96

Heart wall

30

Kidneys

40

Liver

57

Lungs

34

Muscle

9

Ovaries

21

Pancreas

14

Red bone marrow

10

Osteogenic cells

12

Skin

6

Spleen

10

Testes

7

Thymus gland

9

Thyroid

7

Urinary bladder wall

38

Uterus

18

Total body

12

Effective dose (µSv/MBq)a

24

aAssumed radiation weighting factor, wr (formerly defined as quality factor, Q), of 1 for conversion of absorbed dose (Gray or rads) to dose equivalent (Sieverts or rem) for F 18. To obtain radiation absorbed dose in rad/mCi from above table, multiply the dose in μGy/MBq by 0.0037 (eg, 14 μGy/MBq x 0.0037 = 0.0518 rad/mCi).

Effective Dose

The effective radiation dose resulting from a 370-MBq (10-mCi) dose of flortaucipir F 18 is 8.7 mSv in an adult.1

The use of a computed tomography (CT) scan to calculate attenuation correction for reconstruction of flortaucipir F 18 images, as done in positron emission tomography (PET)/CT imaging, will result in additional radiation exposure dependent on the settings used in the CT acquisition.1,2

Enclosed Prescribing Information

Tauvid™ (Flortaucipir F 18 injection) for intravenous use, Lilly

References

1Tauvid [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: May 23, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly